ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Hematologic Malignancies

Hematologic Malignancies

Adding ixazomib to the combination of lenalidomide/dexamethasone resulted in a more than 35% improvement in the risk for disease progression or death in patients with relapsed or refractory multiple myeloma.

Patients with primary plasma cell leukemia experienced high rates of response and improved progression-free survival when treated with bortezomib, dexamethasone plus doxorubicin or cyclophosphamide followed by transplantation.

The efficacy of ponatinib in patients with newly diagnosed CML compared with imatinib remains to be established, as a randomized phase III trial was terminated early due to concerns regarding arterial occlusive events with ponatinib.

Risk-stratification based on a biomarker and associated prophylaxis could help reduce the incidence of graft-vs-host disease in patients undergoing haploidentical transplantation.

We review here the state of the art of diagnosis and treatment of AML and provide insights into the emerging novel biomarkers and therapeutic agents that are anticipated to be useful for the implementation of personalized medicine in AML.

We are ready to move beyond a “one-size-fits-all” approach in AML and join our colleagues treating other malignancies, such as lung cancer, in moving towards a personalized medicine approach.

Recent advances in mantle cell lymphoma include: (1) identification of new pathways to target, (2) novel therapeutics to treat patients with relapsed/refractory disease, and (3) monitoring of minimal residual disease and adoption of a maintenance therapy approach to prevent relapses post induction or post stem cell transplantation.

Pages

Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.